CMS (00867) announced its interim results, with profit attributable to shareholders increasing by 4.77% year-on-year to 986 million yuan.

CMS (00867) announced its mid-term results for 2026, with a revenue increase of 12.5% year-on-year to approximately 4.5 billion yuan, a gross profit increase of 11.4% year-on-year to about 3.221 billion yuan, and a net profit increase of 4.3% year-on-year to 971.5 million yuan. The profit attributable to equity holders increased by 4.77% year-on-year to 986 million yuan, with basic earnings per share of 0.4075 yuan and an interim dividend of 0.1634 yuan per share. In the first half of 2026, the phased effects of CMS's growth engine transition became increasingly evident: the revenue from products related to national centralized purchasing stabilized, while innovative and exclusive drugs served as key drivers for the group's growth, supporting solid increases in both revenue and net profit. Among these, the revenue from innovative and exclusive products reached a total of 1.6987 billion yuan, a year-on-year increase of 19.7%, accounting for 37.7% of total revenue (compared to 1.419 billion yuan in the same period last year, which accounted for 35.5%). The total revenue from drug sales reached approximately 1.709 billion yuan, growing by 20.5% year-on-year, with the revenue share rising to 32.0% (up from 1.419 billion yuan, which accounted for 30.4% in the same period last year). The continuous transformation of innovative achievements is underway: three innovative drugs have been approved for market launch, five innovative drugs (covering six indications) are under review for New Drug Applications (NDA), and three self-researched products (covering five indications) have received approval for Investigational New Drug applications (IND), along with one new collaboration project. The collaborative products include one innovative intravenous iron agent and one original research intravenous iron agent, both already launched in China, with the innovative pipeline and product portfolio progressing as planned. Furthermore, the group has further solidified its specialist scale advantages, and advancements in product registration and commercialization for internationalization continue to be made, establishing a stronger foundation for high-quality sustainable growth.